MAM
GYRE icon

Meeder Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Meeder Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-93
Closed -$6K – 2072
2019
Q1 		$6K Sell
93
-64
-41% -$4.11K ﹤0.01% 1358
2018
Q4 		$9K Buy
+157
New +$11.6K ﹤0.01% 1274

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Meeder Asset Management's GYRE Position: Q2 2019 in Review

Meeder Asset Management sold out of Gyre Therapeutics (GYRE) in Q2 2019, closing a stake of 93 shares — an estimated $6K sold.

Meeder Asset Management first reported a position in GYRE in Q4 2018 and held it in 2 quarters. The position peaked at $9K in Q4 2018. 49 funds tracked by Wall St. Rank hold GYRE as of Q2 2019.

  • Meeder Asset Management reported no remaining Gyre Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Meeder Asset Management sold 93 Gyre Therapeutics shares in Q2 2019, an estimated $6K.
  • Meeder Asset Management first reported a position in Gyre Therapeutics in Q4 2018 and held it in 2 quarters.
  • Meeder Asset Management's Gyre Therapeutics position peaked at $9K in Q4 2018.
  • 49 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2019.

Based on Meeder Asset Management's 13F filing for Q2 2019, filed 5 Aug 2019.